Head to Head Contrast: Eurofins Scientific (OTCMKTS:ERFSF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY)

Eurofins Scientific (OTCMKTS:ERFSF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.


This table compares Eurofins Scientific and SWEDISH ORPHAN/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eurofins Scientific N/A N/A N/A
SWEDISH ORPHAN/S 25.75% 29.63% 18.74%

Earnings and Valuation

This table compares Eurofins Scientific and SWEDISH ORPHAN/S’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eurofins Scientific $4.32 billion 1.74 $264.48 million $22.95 18.65
SWEDISH ORPHAN/S $763.19 million 8.71 $134.73 million $0.50 48.76

Eurofins Scientific has higher revenue and earnings than SWEDISH ORPHAN/S. Eurofins Scientific is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Eurofins Scientific and SWEDISH ORPHAN/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eurofins Scientific 0 1 1 0 2.50
SWEDISH ORPHAN/S 0 0 1 0 3.00

Volatility & Risk

Eurofins Scientific has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, SWEDISH ORPHAN/S has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.


SWEDISH ORPHAN/S beats Eurofins Scientific on 7 of the 10 factors compared between the two stocks.

About Eurofins Scientific

Eurofins Scientific SE, through its subsidiaries, provides various analytical testing services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agro science, agro testing, biopharma, contract development and manufacturing organization, clinical diagnostics, consumer product testing, cosmetics testing, digital testing, electrical and electronics, environment testing, food and feed testing, forensic, genomic, industrial, materials and engineering, medical device, and REACH services. The company serves clients from a range of industries, including the pharmaceutical, food, environmental, and clinical diagnostics sectors. It operates approximately 800 laboratories in 47 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.


Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Receive News & Ratings for Eurofins Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eurofins Scientific and related companies with MarketBeat.com's FREE daily email newsletter.